SE8701921D0 - NEW PHARMACEUTICAL APPLICATION - Google Patents
NEW PHARMACEUTICAL APPLICATIONInfo
- Publication number
- SE8701921D0 SE8701921D0 SE8701921A SE8701921A SE8701921D0 SE 8701921 D0 SE8701921 D0 SE 8701921D0 SE 8701921 A SE8701921 A SE 8701921A SE 8701921 A SE8701921 A SE 8701921A SE 8701921 D0 SE8701921 D0 SE 8701921D0
- Authority
- SE
- Sweden
- Prior art keywords
- tissue
- new pharmaceutical
- pharmaceutical application
- medicament
- damage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Tissue plasminogen activator (t-PA), optionally together with superoxide dismutase (SOD), is used to manufacture a medicament for use in the inhibition of damage to jeopardised tissue during blood reperfusion. The medicament is for preventing damage to tissue following ischaemic attack, e.g. in myocardial tissue, when blood supply is restored.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86204686A | 1986-05-12 | 1986-05-12 | |
US06/862,057 US4976959A (en) | 1986-05-12 | 1986-05-12 | T-PA and SOD in limiting tissue damage |
Publications (2)
Publication Number | Publication Date |
---|---|
SE8701921D0 true SE8701921D0 (en) | 1987-05-11 |
SE8701921L SE8701921L (en) | 1987-11-13 |
Family
ID=27127662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE8701921A SE8701921L (en) | 1986-05-12 | 1987-05-11 | NEW PHARMACEUTICAL APPLICATION |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPH0680015B2 (en) |
AU (1) | AU600724B2 (en) |
BE (1) | BE1001425A4 (en) |
CH (1) | CH672989A5 (en) |
DE (1) | DE3715662A1 (en) |
DK (1) | DK237187A (en) |
FR (1) | FR2600895B1 (en) |
GB (1) | GB2194886B (en) |
IE (1) | IE59895B1 (en) |
LU (1) | LU86875A1 (en) |
NL (1) | NL8701113A (en) |
NZ (1) | NZ220260A (en) |
SE (1) | SE8701921L (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0780784B2 (en) * | 1987-10-23 | 1995-08-30 | 宇部興産株式会社 | Myocardial ischemic injury therapeutic agent based on microcirculatory disorder |
NZ230808A (en) * | 1988-10-24 | 1993-04-28 | Squibb & Sons Inc | Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent |
DE4038563A1 (en) * | 1990-12-04 | 1992-06-11 | Gruenenthal Gmbh | USE OF SUPEROXIDE DISMUTASES FOR PROPHYLAXIS AND / OR TREATMENT OF ORGAN FAILURE IN RISK PATIENTS WITH POLYTRAUMA |
DE19518625C2 (en) * | 1995-05-24 | 1997-08-07 | Buescher Pebueso Beton | Process for sealing concrete pipes and a concrete pipe suitable for carrying out the process |
US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US8680059B2 (en) | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
US7175679B2 (en) | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
US6844315B2 (en) | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
EP1300418A1 (en) | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US7517529B2 (en) | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
EP1904086A2 (en) | 2005-07-05 | 2008-04-02 | Biotempt B.V. | Treatment of tumors |
EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
US8652476B2 (en) | 2009-07-27 | 2014-02-18 | Niigata University | Pharmaceutical composition for treating ischemic events |
WO2011013668A1 (en) * | 2009-07-27 | 2011-02-03 | 国立大学法人新潟大学 | Pharmaceutical composition for treatment of ischemic events |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8003402A (en) * | 1980-06-11 | 1982-01-04 | Leuven Res & Dev Vzw | NEW PLASMINOGEN ACTIVATOR AND PHARMACEUTICAL PREPARATION WITH THROMBOLYTIC ACTION. |
EP0112122B1 (en) * | 1982-12-14 | 1991-08-28 | South African Inventions Development Corporation | Plasminogen activator |
JPS59196824A (en) * | 1983-04-21 | 1984-11-08 | Kowa Co | Adsorption inhibitor |
US4929444A (en) * | 1985-05-28 | 1990-05-29 | Burroughs Wellcome Co. | Low pH pharmaceutical formulation containing t-PA |
DK163174C (en) * | 1985-05-28 | 1992-06-22 | Wellcome Found | VERY CONCENTRATED PARENTERAL SOLUTION OF TISSUE PLASMINOGEN ACTIVATES (T-PA) AND PROCEDURES FOR PREPARING THEM |
AU6334586A (en) * | 1986-05-15 | 1987-12-01 | Emory University | Composition and method for treating a thrombus and embolus |
-
1987
- 1987-05-11 DK DK237187A patent/DK237187A/en not_active Application Discontinuation
- 1987-05-11 DE DE19873715662 patent/DE3715662A1/en active Granted
- 1987-05-11 BE BE8700510A patent/BE1001425A4/en not_active IP Right Cessation
- 1987-05-11 IE IE121087A patent/IE59895B1/en not_active IP Right Cessation
- 1987-05-11 AU AU72704/87A patent/AU600724B2/en not_active Ceased
- 1987-05-11 SE SE8701921A patent/SE8701921L/en unknown
- 1987-05-11 CH CH1788/87A patent/CH672989A5/de not_active IP Right Cessation
- 1987-05-11 NZ NZ220260A patent/NZ220260A/en unknown
- 1987-05-11 FR FR8706551A patent/FR2600895B1/en not_active Expired - Lifetime
- 1987-05-11 GB GB8711058A patent/GB2194886B/en not_active Expired - Fee Related
- 1987-05-11 JP JP62114386A patent/JPH0680015B2/en not_active Expired - Lifetime
- 1987-05-11 NL NL8701113A patent/NL8701113A/en not_active Application Discontinuation
- 1987-05-11 LU LU86875A patent/LU86875A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK237187D0 (en) | 1987-05-11 |
FR2600895B1 (en) | 1993-12-24 |
SE8701921L (en) | 1987-11-13 |
DK237187A (en) | 1987-11-13 |
GB8711058D0 (en) | 1987-06-17 |
IE59895B1 (en) | 1994-04-20 |
AU600724B2 (en) | 1990-08-23 |
CH672989A5 (en) | 1990-01-31 |
DE3715662A1 (en) | 1987-11-19 |
GB2194886B (en) | 1990-04-25 |
LU86875A1 (en) | 1988-01-20 |
IE871210L (en) | 1987-11-12 |
BE1001425A4 (en) | 1989-10-31 |
JPH0680015B2 (en) | 1994-10-12 |
FR2600895A1 (en) | 1988-01-08 |
NZ220260A (en) | 1990-07-26 |
GB2194886A (en) | 1988-03-23 |
AU7270487A (en) | 1987-11-19 |
NL8701113A (en) | 1987-12-01 |
JPS6322026A (en) | 1988-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE8701921D0 (en) | NEW PHARMACEUTICAL APPLICATION | |
FI19991893A (en) | Controlled release of budesonide for oral administration and use of budesonide | |
ATE172359T1 (en) | COLD STERILIZER WITH EXTENDED ACTIVITY | |
DK0698389T3 (en) | Controlled release matrix for pharmaceutical preparations | |
DE3864020D1 (en) | ARRANGEMENT FOR REMOVAL OF ACTIVE AGENTS, LOCALLY USED AGAINST SOLID TUMORS. | |
DE60040345D1 (en) | PROCESS FOR PREPARING A REVERSIBLE INACTIVE, ACIDIFIED PLASMINE COMPOSITION | |
DK463989D0 (en) | PHARMACEUTICAL ACTIVE COMBINATION | |
IS1565B (en) | Process for the preparation of N1-substituted benzimidazole derivatives for therapeutic use | |
SE8602405D0 (en) | NEW FORMULATION | |
DK0460062T3 (en) | Huperzin A analogues | |
TW337997B (en) | Pharmaceutical preparation containing plasminogen activators | |
DE194202T1 (en) | PHARMACEUTICAL COMPOSITION MADE OF GUAR RUBBER AND OTHER ANTIACIDA TO PROTECT THE OESO-GASTRO-DUODENAL Mucous membrane. | |
HUP9801924A2 (en) | Pharmaceutical composition containing sodium-hydrogen-exchange-inhibitors and cardiovascular active agents | |
AU3744889A (en) | Variants of plasminogen activators and processes for their production | |
SE9602644D0 (en) | New use | |
ES2000033A6 (en) | Liquid stable anthelmintic and fungicidal composition based on bithionol sulfoxide. | |
AR030647A1 (en) | PHARMACEUTICAL COMPOSITION WITH SPECIFIC WATER ACTIVITY | |
DK1019037T3 (en) | Drug containing delta-aminolevulinic acid | |
ES2039194T3 (en) | A METHOD OF PREPARING A THROMBOLITICALLY ACTIVE PHARMACEUTICAL COMPOSITION. | |
DK0499679T3 (en) | Therapeutic agent for diabetic gangrene | |
KR890701732A (en) | Improved tissue plasminogen activator | |
KR900016130A (en) | 2-pyridylmethylthio derivatives and ulcer treatments | |
GR77250B (en) | ||
EP0386240A4 (en) | Novel polypeptide compounds | |
TR200102221T2 (en) | Use of moxonidine for treatments after a heart attack |